Copyright © 2012 Hyo-Jeong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
2. J. Ferlay, D. M. Parkin, and E. Steliarova-Foucher, “Estimates of cancer incidence and mortality in Europe in 2008,” European Journal of Cancer, vol. 46, no. 4, pp. 765–781, 2010. View at Publisher · View at Google Scholar · View at Scopus
3. A. Jemal, A. Thomas, T. Murray, and M. Thun, “Cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 52, no. 1, pp. 23–47, 2002. View at Scopus
4. J. A. Kish, R. Bukkapatnam, and F. Palazzo, “The treatment challenge of hormone-refractory prostate cancer,” Cancer Control, vol. 8, no. 6, pp. 487–495, 2001. View at Scopus
5. O. W. Brawley, S. Barnes, and H. Parnes, “The future of prostate cancer prevention,” Annals of the New York Academy of Sciences, vol. 952, pp. 145–152, 2001. View at Scopus
6. Y. Huang, J. Yu, C. Yan, et al., “Effect of small interfering RNA targeting hypoxia-inducible factor-1alpha on radiosensitivity of PC3 cell line,” Urology, vol. 79, no. 3, pp. 744.e17–744.e24, 2011.
7. W. R. Wilson and M. P. Hay, “Targeting hypoxia in cancer therapy,” Nature Reviews Cancer, vol. 11, no. 6, pp. 393–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
8. R. Wang, S. Zhou, and S. Li, “Cancer therapeutic agents targeting hypoxia-inducible factor-1,” Current Medicinal Chemistry, vol. 18, no. 21, pp. 3168–3189, 2011. View at Publisher · View at Google Scholar · View at Scopus
9. M. Yamakawa, L. X. Liu, T. Date et al., “Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors,” Circulation Research, vol. 93, no. 7, pp. 664–673, 2003. View at Publisher · View at Google Scholar · View at Scopus
10. O. Rosmorduc and C. Housset, “Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease,” Seminars in Liver Disease, vol. 30, no. 3, pp. 258–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
11. P. Sooriakumaran and R. Kaba, “Angiogenesis and the tumour hypoxia response in prostate cancer: a review,” International Journal of Surgery, vol. 3, no. 1, pp. 61–67, 2005. View at Publisher · View at Google Scholar · View at Scopus
12. L. Marignol, M. Coffey, M. Lawler, and D. Hollywood, “Hypoxia in prostate cancer: a powerful shield against tumour destruction?” Cancer Treatment Reviews, vol. 34, no. 4, pp. 313–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
13. G. L. Semenza, “Regulation of cancer cell metabolism by hypoxia-inducible factor 1,” Seminars in Cancer Biology, vol. 19, no. 1, pp. 12–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
14. G. Pagès and J. Pouysségur, “Transcriptional regulation of the Vascular Endothelial Growth Factor gene—a concert of activating factors,” Cardiovascular Research, vol. 65, no. 3, pp. 564–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
15. M. Liu, D. Li, R. Aneja et al., “PO2-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway,” Journal of Biological Chemistry, vol. 282, no. 24, pp. 17581–17586, 2007. View at Publisher · View at Google Scholar · View at Scopus
16. L. Emdad, D. Sarkar, Z. Z. Su et al., “Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration,” Pharmacology and Therapeutics, vol. 114, no. 2, pp. 155–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
17. G. Hu, Y. Wei, and Y. Kang, “The multifaceted role of MTDH/AEG-1 in cancer progression,” Clinical Cancer Research, vol. 15, no. 18, pp. 5615–5620, 2009. View at Publisher · View at Google Scholar · View at Scopus
18. L. Song, W. Li, H. Zhang et al., “Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer,” Journal of Pathology, vol. 219, no. 3, pp. 317–326, 2009. View at Publisher · View at Google Scholar · View at Scopus
19. E. Noch, M. Bookland, and K. Khalili, “Astrocyte-elevated gene-1 (AEG-1) induction by hypoxia and glucose deprivation in glioblastoma,” Cancer Biology and Therapy, vol. 11, no. 1, pp. 32–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
20. L. Emdad, S. G. Lee, Z. Z. Su et al., “Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 50, pp. 21300–21305, 2009. View at Publisher · View at Google Scholar · View at Scopus
21. L. Liu, J. Wu, Z. Ying et al., “Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion,” Cancer Research, vol. 70, no. 9, pp. 3750–3759, 2010. View at Publisher · View at Google Scholar · View at Scopus
22. X. X. He, Y. Chang, F. Y. Meng, et al., “MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo,” Oncogene, vol. 31, no. 28, pp. 3357–3369, 2012. View at Publisher · View at Google Scholar
23. S. G. Lee, Z. Z. Su, L. Emdad, D. Sarkar, and P. B. Fisher, “Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring-phosphatidylinositol 3-kinase and c-Myc,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17390–17395, 2006. View at Publisher · View at Google Scholar · View at Scopus
24. J. Li, L. Yang, L. Song et al., “Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1,” Oncogene, vol. 28, no. 36, pp. 3188–3196, 2009. View at Publisher · View at Google Scholar · View at Scopus
25. D. B. Jung, H. J. Lee, S. J. Jeong et al., “Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells,” Biological and Pharmaceutical Bulletin, vol. 34, no. 6, pp. 850–855, 2011. View at Publisher · View at Google Scholar · View at Scopus
26. H. J. Lee, N. J. Seo, S. J. Jeong et al., “Oral administration of penta-O-galloyl-β-d-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition,” Carcinogenesis, vol. 32, no. 6, pp. 804–811, 2011. View at Publisher · View at Google Scholar · View at Scopus
27. K. Y. Park, H. J. Lee, S. J. Jeong et al., “1,2,3,4,6-penta-o-galloly-beta-D-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1α and signaling in LNCaP prostate cancer cells,” Biological and Pharmaceutical Bulletin, vol. 33, no. 11, pp. 1835–1840, 2010. View at Publisher · View at Google Scholar · View at Scopus
28. B. S. Feng and S. R. Li, “Studies on the chemical components of Dan-shen (Salvia miltiorrhiza Bunge) (author's transl),” Acta Pharmaceutica Sinica, vol. 15, no. 8, pp. 489–494, 1980. View at Scopus
29. Z. T. Li, B. J. Yang, and G. E. Ma, “Chemical studies of Salvia miltiorrhiza f. Alba,” Acta Pharmaceutica Sinica, vol. 26, no. 3, pp. 209–213, 1991. View at Scopus
30. W. Chen, Y. Luo, L. Liu et al., “Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin -mediated cyclin D1 expression and Rb phosphorylation,” Cancer Prevention Research, vol. 3, no. 8, pp. 1015–1025, 2010. View at Publisher · View at Google Scholar · View at Scopus
31. D. Xu, T.H. Lin, S. Li, et al., “Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells,” Cancer Letters, vol. 316, no. 1, pp. 11–22, 2011.
32. J. H. Kim, S. J. Jeong, T. R. Kwon, et al., “Cryptotanshinone enhances TNF-alpha-induced in chronic myeloid leukemia KBM-5 cells,” Apoptosis, vol. 16, no. 7, pp. 696–707, 2011.
33. I. J. Park, M. J. Kim, O. J. Park et al., “Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation,” Cancer Letters, vol. 298, no. 1, pp. 88–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
34. E. A. Jaffe, R. L. Nachman, C. G. Becker, and C. R. Minick, “Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria,” Journal of Clinical Investigation, vol. 52, no. 11, pp. 2745–2756, 1973. View at Scopus
35. B. K. Yoo, L. Emdad, S. G. Lee et al., “Astrocyte elevated gene-1 (AEG-1): a multifunctional regulator of normal and abnormal physiology,” Pharmacology and Therapeutics, vol. 130, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
36. S. Doublier, D. C. Belisario, M. Polimeni, et al., “HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast,” BMC Cancer, vol. 12, article 4, 2012. View at Publisher · View at Google Scholar
37. H. Zhong, A. M. De Marzo, E. Laughner et al., “Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases,” Cancer Research, vol. 59, no. 22, pp. 5830–5835, 1999. View at Scopus
38. S. G. Lee, Z. Z. Su, L. Emdad, D. Sarkar, T. F. Franke, and P. B. Fisher, “Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling,” Oncogene, vol. 27, no. 8, pp. 1114–1121, 2008. View at Publisher · View at Google Scholar · View at Scopus
39. M. Calvani, A. Rapisarda, B. Uranchimeg, R. H. Shoemaker, and G. Melillo, “Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells,” Blood, vol. 107, no. 7, pp. 2705–2712, 2006. View at Publisher · View at Google Scholar · View at Scopus
40. C. P. S. Potter and A. L. Harris, “Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer,” British Journal of Cancer, vol. 89, no. 1, pp. 2–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
41. M. Choschzick, L. Woelber, S. Hess et al., “Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases,” Virchows Archiv, vol. 456, no. 5, pp. 483–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
42. A. J. Majmundar, W. J. Wong, and M. C. Simon, “Hypoxia-inducible factors and the response to hypoxic stress,” Molecular Cell, vol. 40, no. 2, pp. 294–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. A. L. Harris, “Hypoxia—a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp. 38–47, 2002. View at Scopus
44. B. K. Yoo, L. Emdad, S. G. Lee et al., “Astrocyte elevated gene-1 (AEG-1): a multifunctional regulator of normal and abnormal physiology,” Pharmacology and Therapeutics, vol. 130, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
45. Z. Ying, J. Li, and M. Li, “Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond,” Cell & Bioscience, vol. 1, no. 1, p. 36, 2011.
46. P. Jaakkola, D. R. Mole, Y. M. Tian et al., “Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation,” Science, vol. 292, no. 5516, pp. 468–472, 2001. View at Scopus
47. D. Mottet, V. Dumont, Y. Deccache et al., “Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 31277–31285, 2003. View at Publisher · View at Google Scholar · View at Scopus
48. J. M. Hur, J. S. Shim, H. J. Jung, and H. J. Kwon, “Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro,” Experimental and Molecular Medicine, vol. 37, no. 2, pp. 133–137, 2005. View at Scopus
49. D. S. Shin, H. N. Kim, D. S. Ki et al., “Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells,” Cancer Research, vol. 69, no. 1, pp. 193–202, 2009. View at Publisher · View at Google Scholar · View at Scopus